Superficial bladder cancer treated by intravesical bacillus Calmette-Guerin or adriamycin: Multicenter study interim report

Urology

Volumn 30, Issue 6, 1987, Pages 520-528

  Khanna, Om P ^a,b,c,d,e,f   Son, Daniel L ^a,b,c,d,e,f   Mazer, Howard ^a,b,c,d,e,f   Read, John ^a,b,c,d,e,f   Nugent, Dennis ^a,b,c,d,e,f   Cottone, Robert ^a,b,c,d,e,f   Heeg, Michael ^a,b,c,d,e,f   Rezvan, Masoud ^a,b,c,d,e,f   Viek, Nicholas ^a,b,c,d,e,f   Friedmann, Marvin ^a,b,c,d,e,f  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b Wilkes Barre General Hospital   (United States)

^c Paoli Memorial Hospital   (United States)

^d Bridgeton Hospital ^*  (United States)

^e Elmer Community Hospital ^*  (United States)

^f Helene Fuld Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DOXORUBICIN;

BLADDER CANCER; CANCER RECURRENCE; FOLLOW UP; MAJOR CLINICAL STUDY; NORMAL HUMAN; SUPERFICIAL CANCER; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVESICAL; BCG VACCINE; BLADDER NEOPLASMS; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIALS; COMPARATIVE STUDY; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMAN; MALE; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; TIME FACTORS;

EID: 0023553286     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/0090-4295(87)90429-8     Document Type: Article

References (18)

1. Bladder cancer: overview
2. A case-control study of female bladder cancer
3. Bladder cancer-epidemiology
4. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder
5. Disease progression in BCG treated patients with transitional cell carcinoma of the bladder
6. Management of patients with superficial bladder cancer with an emphasis on the use of intravesical therapy
7. The biology and treatment of superficial bladder cancer
8. Prophylaxis of recurrent bladder cancer with bacillus Calmette-Guerin
9. Bladder carcinoma in patients 40 years old or less
10. Adjuvant therapy of T1 bladder carcinoma: preliminary of an EROTC randomized study
11. Intravesical bacillus Calmette-Guerin therapy: a prospective randomized study comparing the efficacy of maintenance versus single course therapy
12. The use of bacillus Calmette-Guerin in the therapy of bladder carcinoma in situ
13. Bacillus Calmette-Guerin immunotherapy for bladder cancer
14. Six weekly intravesical BCG instillations not optimal for treatment of superficial bladder tumors
15. The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin
16. Treatment of recurrent superficial transitional cell carcinoma of the bladder with intravesical bacillus Calmette-Guerin (BCG)